非肌层浸润性膀胱癌接受卡介苗治疗的当代结局:对临床试验设计的启示
该研究回顾性分析了2004年至2018年间在一家三级癌症中心接受充分卡介苗治疗的542例非肌层浸润性膀胱癌患者,其中90%为欧洲泌尿外科学会高危疾病,32%存在原位癌。中位随访47.8个月,1年、3年和5年无高级别复发生存率分别为81%、76%和74%,无进展生存率分别为97%、93%和92%。5年进展为肌层浸润仅见于高危患者,其无进展生存率为91%(log-rank检验,p=0.024)。当代队列结局显著优于既往研究,可为临床试验设计提供基准数据。
要点
- 充分卡介苗治疗的当代队列5年无高级别复发生存率为74%,无进展生存率为92%。
- 5年进展为肌层浸润仅见于高危患者,其无进展生存率为91%(p=0.024)。
- 该数据可用于临床试验的把握度计算和作为非随机研究的比较基准。
核心结论
- 接受充分卡介苗治疗的当代非肌层浸润性膀胱癌患者结局显著优于既往研究,可作为临床试验设计基准。
研究设计与样本
- 回顾性队列研究,纳入2004年1月至2018年8月在一家三级癌症中心接受充分卡介苗治疗的542例非肌层浸润性膀胱癌患者。
主要发现
- 542例中518例(90%)为欧洲泌尿外科学会高危疾病,175例(32%)存在原位癌。
- 中位随访47.8个月,1年、3年和5年无高级别复发生存率分别为81%、76%和74%。
- 1年、3年和5年无进展生存率分别为97%、93%和92%。
- 5年进展为肌层浸润仅见于高危患者,其无进展生存率为91%(log-rank检验,p=0.024)。
关键数值与推荐
- 充分卡介苗治疗的定义依据美国食品药品监督管理局标准。
- 卡介苗无反应疾病状态依据美国食品药品监督管理局定义。
临床怎么用
- 本研究提供的基准结局数据可用于设计临床试验时计算样本量和把握度。
- 该数据可作为非随机研究比较的基准。
局限性
- 回顾性研究设计。
- 单中心三级癌症中心数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Recurrent disease after bacillus Calmette-Guérin treatment presents a therapeutic challenge. To aid trial development, the U.S. Food and Drug Administration defined "adequate bacillus Calmette-Guérin" therapy and adopted the "bacillus Calmette-Guérin unresponsive" disease state. Available data for efficacy benchmark comparison are outdated, leading to concerns about appropriate control arms and sample size calculations. We describe a contemporary cohort of patients with nonmuscle-invasive bladder cancer treated with intravesical bacillus Calmette-Guérin, and provide benchmark outcomes data. MATERIALS AND METHODS: We retrospectively reviewed patients receiving adequate bacillus Calmette-Guérin therapy at a tertiary cancer center between January 2004 and August 2018. Unadjusted univariable analysis was conducted using the Pearson chi-square test. Kaplan-Meier estimates for recurrence-free survival-high grade, progression-free survival-muscle-invasive bladder cancer and overall survival were used to create survival curves and compared using the log-rank test. RESULTS: Of the 542 patients who received adequate bacillus Calmette-Guérin, 518 (90%) had European Association Urology high risk disease, with carcinoma in situ present in 175 (32%). With a median followup of 47.8 months, freedom from high grade recurrence at 1, 3 and 5 years was 81%, 76% and 74%, respectively, and progression-free survival was 97%, 93% and 92%. Progression to muscle invasion at 5 years was exclusively seen in patients with high risk disease (progression-free survival 91%; log-rank test, p=0.024). CONCLUSIONS: A contemporary cohort of patients with nonmuscle-invasive bladder cancer treated with adequate bacillus Calmette-Guérin demonstrated markedly better outcomes than seen in prior studies. These data could be used in the design of clinical trials, to guide power calculations, as well as serve as benchmarks for comparison to evaluate nonrandomized studies.
引用
- Matulay JT, Li R, Hensley PJ, et al. Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guérin: Implications for Clinical Trial Design. J Urol. 2021. PMID: 33502236. doi:10.1097/JU.0000000000001633
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。